Emulate, Inc.

📍 Boston, United States🗓 Founded 2014👥 122 employees💰 Last funded Mar 2024
Biotechnology Research🌐 emulatebio.com
Website LinkedIn
Emulate Inc. is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. Our lab-ready Human Emulation System® includes three components: Zoë® Culture Module, Organ-Chips, and analytical software applications. The platform provides a window into the inner workings of human biology and disease—offering researchers a new technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Research conducted using our Organ-Chips has been published in high-impact scientific journals, including Science. In addition, Organ-Chips have been acquired by the Museum of Modern Art (MoMA) in New York for their permanent collection and have also been awarded Product Design of the Year 2015 by London’s Design Museum.
6
Total investors
2
Early stage
3
Mid stage
1
Late stage
2014
Founded

Investors

6 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
5
China
1
Investor activity2014–2024 · investors recorded per year
2014120151201812019220241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Emulate, Inc.?
Emulate, Inc. has 6 investors on record on gritt.io, including 2 early-stage backers, 3 mid-stage and 1 late-stage investors.
When did Emulate, Inc. last raise funding?
The most recent investment in Emulate, Inc. recorded on gritt.io was in March 2024.
When was Emulate, Inc. founded?
Emulate, Inc. was founded in 2014.
What industry is Emulate, Inc. in?
Emulate, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Emulate, Inc. based?
Emulate, Inc. is headquartered in Boston, United States.